Disulfiram/copper - Cantex Pharmaceuticals

Drug Profile

Disulfiram/copper - Cantex Pharmaceuticals

Alternative Names: CX 02; Disulfiram/copper gluconate - Cantex Pharmaceuticals; DSF-Cu

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Cantex Pharmaceuticals
  • Class Antineoplastics; Heavy metals; Small molecules
  • Mechanism of Action Aldehyde dehydrogenase inhibitors; Cell death stimulants; Proteasome inhibitors; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Brain metastases; Breast cancer; Glioblastoma

Most Recent Events

  • 03 Feb 2017 Phase-I clinical trials in Brain metastases (PO) (Cantex pipeline, February 2017)
  • 03 Feb 2017 Phase-I clinical trials in Breast cancer (Metastatic disease) (PO) (Cantex pipeline, February 2017)
  • 03 Feb 2017 Phase-I clinical trials in Glioblastoma (Recurrent) (PO) before February 2017 (Cantex pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top